THE POLYMORPHISM OF THE VKORC1 (C1173T) GENE, DETERMINING INDIVIDUAL SUSCEPTIBILITY TO WARFARIN, IN POPULATIONS OF INDIGENOUS PEOPLES OF SELKUPS AND TUNDRA NENETS AND IN THE RUSSIANS OF NORTHERN SIBERIA
Abstract
In relation with determining population sensitivity to warfarin the study of the VKORC1 C1173T polymorphism in Northern Siberia populations of indigenous Samoedic peoples (Selkups and Tundra Nenets) and also in Russians has been conducted. It was revealed, the mutational genotype VKORC1 1173TT considerably dominations in studied Samoedic populations as compared with Russians. The frequencies of genotype VKORC1 1173TT were 57,1 % in Tundra Nenets, 71,8 % in Selkups and in 13,6 % Russians. The frequencies of VKORC1 C1173T allele in Tundra Nenets (74,7 %) and Selkups (84,6 %) essentially and reliably are above ones in Russians of Northern Siberia (36,9 %). Our data can be used in the protocols of recommendations for dosing warfarin with a view to reaching at most safe and efficient therapy in populations of native residents of Northern Siberia.
Keywords
575.174.015.3:615.273.53:572.79 (1-925.14)
About the Authors
Roza Pavlovna Korchagina
Institute of Citology and Genetics of the Siberian Division of the RAS Novosibirsk
Russian Federation
Russian Federation
Ludmila Pavlovna Osipova
Institute of Citology and Genetics of the Siberian Division of the RAS Novosibirsk
Russian Federation
Russian Federation
Natalya Alexandrovna Vavilova
Institute of Citology and Genetics of the Siberian Division of the RAS Novosibirsk
Russian Federation
Russian Federation
Elena Nikolaevna Voronina
Institute of Chemo biology and fundamental Medicine of the Siberian Division of the RAS, Novosibirsk
Russian Federation
Russian Federation
Maxim Leonidovich Filipenko
Institute of Chemo biology and fundamental Medicine of the Siberian Division of the RAS Novosibirsk
Russian Federation
Russian Federation
References
1. Дебец, Г. Ф. Селькупы (антропологический очерк) [Текст] / Г. Ф. Дебец // Труды института этнографии. - М.; Л.: Изд-во АН СССР, 1947.
2. Осипова, Л. П. Генетические маркеры иммуноглобулинов (система Gm) для оценки процессов миграции и метисации в популяциях человека в Северной Сибири [Текст] / Л. П. Осипова // Сибирский экологический журнал. - 1994. - Т. 1. - № 2.
3. Панченко, Е. П. Венозные тромбозы в терапевтической клинике. Факторы риска и возможности профилактики [Текст] / Е. П. Панченко // Сердце. - 2002. - Т. 1. - № 4. - Вып. 4.
4. Сироткина, О. В. Аллельные варианты CYP2C9*2 и CYP2C9*3 гена цитохрома CYP2C9 в популяции Санкт-Петербурга и их клиническое значение при антикоагулянтной терапии варфарином [Текст] / О. В. Сироткина, А. С. Улитина, А. Е. Тараскина и др. // Российский кардиологический журнал. - 2004. - № 6.
5. Сычев, Д. А. Генетическая основа чувствительности к непрямым антикоагулянтам: фокус на полиморфизм генов VKORC1 и APOE [Текст] / Д. А Сычев, И. В. Игнатьев, В. Г. Кукес // Российский кардиологический журнал. - 2005. - Т. 55.
6. Сычев, Д. А. Фармакогенетика непрямых антикоагулянтов: значение генотипа в повышении эффективности и безопасности терапии [Текст] / Д. А. Сычев, Е. С. Кропачева, И. В. Игнатьев и др. // Кардиология. - 2006. - № 7.
7. Caldwell, M. D. CYP4F2 genetic variant alters required warfarin dose [Text] / M. D. Caldwell, T. Awad, J. A. Johnson // Blood. - 2008. - Vol. 111. - No. 8.
8. Crawford, D. VKORC1 common variation and bone mineral density in the third national health and nutrition examination survey [Text] / D. Crawford, K. Brown-Gentry, M. Rieder // PLoS ONE. - 2010. - Vol. 5. - No. 12.
9. D`Andrea, G. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin [Text] / G. D`Andrea, R. L. D`Ambrosio, P. D. Perna et al. // Blood. - 2005. - Vol. 105. - No. 2.
10. D`Andrea, G. Oral anticoagulations: Pharma-cogenetics Relationship between genetic and non-genetic factors [Text] / G. D`Andrea, R. L. D`Ambro-sio, M. Margaglione // Blood Reviews. - 2008. - Vol. 22.
11. Lacut, K. Vitamin K epoxide reductase genetic polymorphism is associated with venous thromboem-bolism: results from the EDITH study [Text] / K. Lacut, C. Larramendy-Gozalo, G. Le Gal et al. // Journal of Thrombosis and Haemostasis. - 2007. - Vol. 5.
12. Larramendy-Gozalo, C. Genetic polymorphism of vitamin K epoxide reductase (VKORC1) 1173C>T in a Chinese and a Caucasian population [Text] / C. Larramendy-Gozalo, J. Q. Yang, C. L. Verstuyft et al. // Pharmacology and Toxicology. - 2006. - Vol. 98.
13. Lee, M. VKORC1 haplotypes in five East-Asian populations and Indians [Text] / M. Lee, C. Chen, H. Chuang // Pharmacogenomics. - 2009. - Vol. 10. - No. 10.
14. Limdi, N. A. Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups [Text] / N. A. Limdi, M. Wadelius, Cavallari L. et al. // Blood. - 2010. - Vol. 115. - No. 18.
15. Oldenburg, J. Vitamin K epoxide reductase complex subunit 1 (VKORC1): the key protein of the vitamin K cycle [Text] / J. Oldenburg, C. G. Bevans, C. R. Muller, M. Watzka // Antioxid Redox Signal. - 2006. - Vol. 8. - No. 3 - 4.
16. Oldenburg, J. VKORC1: molecular target of coumarins [Text] / J. Oldenburg, M. Watzka, S. Rost, C. R. Muller // Journal of Thrombosis and Haemostasis. - 2007. - Vol. 5. - No. 1.
17. Osman, A. Main gaplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records [Text] / A. Osman, C. Enstrom, K. Arbring, P. Soderkvist, L. Lindahl // Journal of Thrombosis and Haemostasis. - 2006. - Vol. 4.
18. Reitsma, P. H. C1173T dimorphism in the VKORC1 gene determines coumarin sensitivity and bleeding risk [Text] / P. H. Reitsma, J. F. van der Heijden, A. P. Groot, F. R. Rosendaal, H. R. Buller // PLOS Medicine. - 2005. - Vol. 2. - No. 10.
19. Sirotkina, O. The vitamin K epoxide reductase gene polymorphisms and pharmacogenetics of warfarin [Text] / O. Sirotkina, A. Ulitina, A. Markov, T. Vavilova // Journal of Thrombosis and Haemostasis. - 2007. - Vol. 5. - No. 2.
20. Suh, J. W. Vitamin K epoxide reductase complex subunit 1 gene polymorphism is associated with atherothrombotic complication after drug-eluting stent implantation: 2 - Center prostective cohort study [Text] / J. W. Suh, S. H. Baek, J. S. Park et al. // Am. Heart. J. - 2009. - Vol. 157. - No. 5.
21. Wadelius, M. Common VKORC1 and GGCX polymorphisms associated with warfarin dose [Text] / M. Wadelius, L. Y. Chen, K. Downes et al. // Pharmacogenomics Journal. - 2005. - Vol. 5.
22. Wang, Y. Regulatory polymorphism in Vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement / Y. Wang, H. Chen, K. M. Moramy // Blood. - 2008. - Vol. 112. - No. 4.
Review
For citations:
Korchagina R.P., Osipova L.P., Vavilova N.A., Voronina E.N., Filipenko M.L. THE POLYMORPHISM OF THE VKORC1 (C1173T) GENE, DETERMINING INDIVIDUAL SUSCEPTIBILITY TO WARFARIN, IN POPULATIONS OF INDIGENOUS PEOPLES OF SELKUPS AND TUNDRA NENETS AND IN THE RUSSIANS OF NORTHERN SIBERIA. The Bulletin of Kemerovo State University. 2012;(1):19-23. (In Russ.)
Views:
217
Email this article 